Top Markets
#1 Islamic Coin Islamic Coin +151.22%
#2 Akedo Akedo +76.34%
#3 Velvet Velvet +52.62%
#4 Glidr Glidr +51.75%
#5 DOVU DOVU +47.94%
#6 Black Phoenix Black Phoenix +33.93%
#7 Cross Cross +31.13%
#8 Cap Cap +21.55%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +19.55%
#10 DoubleZero DoubleZero +14.82%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
HVIVO plc HVIVO plc

HVIVO plc

HVO
Rank in Stocks #39192
hVIVO plc (HVO) operates as a premier full-service Contract Research... hVIVO plc (HVO) operates as a premier full-service Contract Research Organisation (CRO) focused on early-phase clinical development, globally recognized as the leader in human challenge trials. The company provides a complete spectrum of clinical development services to a wide-ranging and growing client base, which includes seven of the world's ten largest biopharmaceutical companies. A key specialisation for hVIVO is orchestrating human challenge trials across numerous infectious and respiratory diseases, utilising its advanced, London-based quarantine facility, the largest of its kind globally. Additionally, the company offers extensive virology and immunology laboratory services through its hLAB division. Through its German subsidiary, CRS, hVIVO manages a 120-bed capacity across sites in Mannheim and Kiel, delivering early-phase clinical trial expertise, including first-in-human and proof-of-concept studies. Its other subsidiary, Venn Life Sciences, contributes to the biopharma sector by providing specialist early drug development consulting and biometry services. The Group collectively offers integrated drug development solutions, covering stages from preclinical research up to Phase II trials, supported by patient recruitment via FluCamp. Moreover, its five clinical sites facilitate outpatient Phase II and III trials, ensuring a streamlined and effective transition from drug discovery to late-stage development.
Share Price
$0.08850547
Market Cap
$609.27K
Change (1 day)
-2.92%
Change (1 year)
-36.17%
Country
GB
Trade HVIVO plc (HVO)

Category

Healthcare
Operating Margin for HVIVO plc (HVO)
Operating Margin as of 2026 TTM: 0.00%
According to HVIVO plc latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for HVIVO plc from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.97% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00% -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
31.23% -
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.